Navigation Links
Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy
Date:12/8/2009

DURHAM, N.C., Dec. 8 /PRNewswire/ -- Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension. The 12-week double-blind placebo controlled Phase 2 study investigated the effects of a novel low dose combination of amiloride HCl and spironolactone in obese adults with treatment-resistant hypertension and statistically met its primary endpoint. HTI was assisted in the successful execution of this trial by Cato Research Ltd., a global contract research and development organization ("CRO") that is affiliated with Cato BioVentures.

"HTI remained as virtual as possible during these challenging economic times and to do this we have strategically leveraged the clinical and regulatory expertise of Cato Research in reaching this important clinical milestone for the company," said Daniel Pharand, CEO of HTI.

Obese patients were enrolled in the study with all experiencing uncontrolled hypertension while taking 3 or more anti-hypertensive medications. After only one month of treatment with HTI101, there was a significant decrease in both systolic and diastolic blood pressure.

"We are pleased to see such a strong response of HTI-101 in this important patient population and feel that this could be a new tool for treating unabated hypertension," said Allen Cato, M.D., Ph.D., CEO of Cato Research Ltd.

HTI obtained the core technology through an exclusive patent a license agreement with the University of Alabama Research Foundation ("UABRF").

About Hemodynamic Therapeutics, Inc.

HTI was formed in 2004 as a majority-owned portfolio company of Cato BioVentures. Through its strategic development relationship with Cato BioVentures and its contract research and development affiliate, Cato Research Ltd., HTI executed its Phase 2 development program for HTI-101, a novel small molecule combination therapy for obesity-related hypertension (ORH), one of the world's fastest growing cardiovascular disease markets. For more information, visit the company's web site at http://www.hemodynamictx.com.

About Cato BioVentures

Cato BioVentures is the venture capital affiliate of Cato Research Ltd. For over 20 years, Cato BioVentures has assisted entrepreneurs and established management teams in building successful life science companies. Through strategic CRO service agreements with Cato Research, Cato BioVentures invests its in-kind CRO Service Capital in innovative therapeutics, medical devices, diagnostics and platform tools and technologies for improved drug discovery and development, offering promising life science companies immediate access to a broad range of essential CRO services on a noncash basis. Access to these time-critical CRO services enables management to achieve key value-added development and regulatory milestones with less reliance on other sources of capital. Cato BioVentures has offices in Boston's Bay Colony, Research Triangle Park, Montreal, and Silicon Valley. For more information, visit the company's web site at http://www.catobioventures.com.

About Cato Research Ltd.

Founded in 1988 by Allen Cato, M.D., Ph.D., and Lynda Sutton and headquartered near Research Triangle Park, Cato Research is a global, full-service contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, medical device, and medical diagnostic industries. With a staff of more than 300 employees located in the United States, Europe, Canada, Israel, India and South Africa, Cato Research's services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. For more information, visit the company's web site at http://www.cato.com.

SOURCE Hemodynamic Therapeutics, Inc.


'/>"/>
SOURCE Hemodynamic Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest laser ... the first of its kind in the area ... through advanced laser treatment. The physician-owned and operated ... Suncoast by storm with its revitalizing skin ... advanced multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
(Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, Inc. ... the previously announced underwritten secondary offering of 11,027,558 shares ... consisting of affiliates of Blackstone and Goldman Sachs.  The ... initial price of $96.45 per share. The selling stockholders ...  Neither Zimmer Biomet nor any of its directors, officers ...
Breaking Medicine Technology:
(Date:2/6/2016)... St. Petersburg, FL (PRWEB) , ... February 06, 2016 , ... ... AsSeenOnTV.pro are pleased to announce the launch of a new DRTV campaign with Belly ... rug. If having tried everything from sprays to puppy pads and find nothing works, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... ... 05, 2016 , ... Successful recruitment and retention efforts, new ... initiatives have all marked the last 12 months at Roswell Park Cancer Institute ... nation’s oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments of ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... announce the addition of micro-needling services in their Napa Valley office. The technique ... of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 , ... ... the Scarborough General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned ... the Scarborough Hospital. He successfully completed his first three-year term as chief and began ...
Breaking Medicine News(10 mins):